Friday, June 5, 2015

Rituxan Cost-Effective Choice After TFN Inhibitors Fail (CME/CE)

(MedPage Today) -- For RA patients, rituximab is equivalent to IV abatacept in safety and efficacy
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)